Goldman Sachs (NYSE:GS) analyst Goldman Sachs maintained a Hold rating on Edwards Lifesciences on Tuesday, setting a price target of $105, which is approximately 8.46% below the present share price of $114.7.
expects Edwards Lifesciences to post earnings per share (EPS) of $0.79 for the third quarter of 2021.
The current consensus among 17 TipRanks analysts is for a Moderate Buy rating of shares in Edwards Lifesciences, with an average price target of $121.
The analysts price targets range from a high of $135 to a low of $105.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.38 billion and a net profit of $441.9 million. The company's market cap is $71.5 billion.
According to TipRanks.com, Goldman Sachs analyst Goldman Sachs is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 10.1% and a 58.53% success rate.
Incorporated in 1958, California-based Edwards Lifesciences Corp (NYSE:EW). is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.